Open letter from Genentech

Article

Click here to read Genentech's open letter to ophthalmologists, outlining its reason for imposing restrictions on the use of Avastin.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
Related Content
A cup of coffee and a pair of glasses sit on a desk, alongside a keyboard and notebook. Image credit: ©karandaev – stock.adobe.com

Study: Oral caffeine intake increases inner electro-retinal activity in young adults

Lynda Charters
October 3rd 2024
Article

Investigators studied global-flash multifocal electroretinogram responses

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A patient undergoes an ocular exam in a clinic. Image credit: ©rocketclips – stock.adobe.com

Novaliq and Laboratoires Théa announce European Commission approval of ciclosporin 0.1% eye drops solution

Martin David Harp
October 2nd 2024
Article

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

An AI-generated image of an eye with genetic material surrounding it. Image credit: ©Iftikhar alam – stock.adobe.com

The latest genetic research from this summer’s retina conferences

Hattie Hayes;Lynda Charters
October 2nd 2024
Article

Gene therapy was a major topic at the 2024 EURETINA and Retina Society meetings

Two business professionals shake hands with a cityscape in the background

Aurion Biotech announces commercial launch of neltependocel (Vyznova) in Japan

Martin David Harp
Published: September 27th 2024 | Updated: September 27th 2024
Article

Neltependocel has received both regulatory and reimbursement approval in Japan

© 2024 MJH Life Sciences

All rights reserved.